Y-Box Binding Protein-1: A Neglected Target in Pediatric Brain Tumors?

Abstract Brain and central nervous system tumors represent the most common childhood solid tumors. Comprising 21% of all pediatric cancers, they remain leading cause cancer-related mortality morbidity in childhood. Due to advances neurosurgical technique, radiotherapy use combination therapy, survival rates have generally increased. However, by lesion itself, its surgical removal subsequent treatment, survivors are at high risk long-term neurocognitive sequelae secondary cancer. Clearly, improvements diagnosis treatment needed. Accordingly, current is evolving away from conventional, uniform therapy towards risk-stratified regimens molecularly-targeted therapies, with aim diminishing adverse side effects while minimizing disease recurrence. The multifunctional oncoprotein Y-box binding protein 1 (YB-1) may serve as one such molecular target. Increased YB-1 levels been reported a number brain tumors, where appears facilitate advancement malignant phenotypes. These include proliferation, invasion, resistance well maintenance tumor-initiating cells. Here we evaluate literature show how modulates signaling pathways driving each these We also review regulation transcriptional, translational, posttranslational subcellular level argue that there strong sufficient evidence support development biomarker future therapeutic target